{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:34:26Z","timestamp":1776742466923,"version":"3.51.2"},"reference-count":92,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.mayocp.2011.11.007","type":"journal-article","created":{"date-parts":[[2012,2,2]],"date-time":"2012-02-02T09:29:48Z","timestamp":1328174988000},"page":"161-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["My Treatment Approach to Patients With Diffuse Large B-Cell Lymphoma"],"prefix":"10.1016","volume":"87","author":[{"given":"James O.","family":"Armitage","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.mayocp.2011.11.007_bib1","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/1097-0142(197203)29:3<630::AID-CNCR2820290316>3.0.CO;2-Q","article-title":"Combination sequential chemotherapy in advanced reticulum cell sarcoma","volume":"29","author":"Levitt","year":"1972","journal-title":"Cancer"},{"issue":"7901","key":"10.1016\/j.mayocp.2011.11.007_bib2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(75)91142-3","article-title":"Advanced diffuse histiocytic lymphoma, a potentially curable disease","volume":"1","author":"DeVita","year":"1975","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mayocp.2011.11.007_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2007-01-041871","article-title":"How I treat patients with diffuse large B-cell lymphoma","volume":"110","author":"Armitage","year":"2007","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.mayocp.2011.11.007_bib4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma; the International Non-Hodgkin's Lymphoma Prognostic Factors Project","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.mayocp.2011.11.007_bib5","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.mayocp.2011.11.007_bib6","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","article-title":"Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era","volume":"28","author":"Ziepert","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2011.11.007_bib7","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"issue":"15S","key":"10.1016\/j.mayocp.2011.11.007_bib8","first-page":"504s","article-title":"R-CHOP14 versus R-CHOP21: results of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma","volume":"29","author":"Cunningham","year":"2011","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.mayocp.2011.11.007_bib9","article-title":"R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the second interim analysis of the LNH03-6B GELA Study","volume":"22","author":"Delarue","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.mayocp.2011.11.007_bib10","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","article-title":"Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial","volume":"378","author":"Recher","year":"2011","journal-title":"The Lancet"},{"issue":"12","key":"10.1016\/j.mayocp.2011.11.007_bib11","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1056\/NEJMoa042040","article-title":"ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma","volume":"352","author":"Reyes","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2011.11.007_bib12","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<154::AID-CNCR21>3.0.CO;2-T","article-title":"Testicular lymphoma is associated with a high incidence of extranodal recurrence","volume":"88","author":"Fonseca","year":"2000","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.mayocp.2011.11.007_bib13","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1182\/blood-2007-07-101402","article-title":"Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report","volume":"111","author":"Doolittle","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mayocp.2011.11.007_bib14","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3324\/haematol.2011.041277","article-title":"Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse","volume":"96","author":"Villa","year":"2011","journal-title":"Haematologica"},{"issue":"3A","key":"10.1016\/j.mayocp.2011.11.007_bib15","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1083-8791(00)70060-7","article-title":"High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma","volume":"6","author":"Alvarnas","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 4","key":"10.1016\/j.mayocp.2011.11.007_bib16","article-title":"Systemic and intrathecal chemotherapy followed by high-dose chemotherapy with autologous stem cell aggressive lymphomas; a potentially curative approach?","volume":"22","author":"Korfel","year":"2011","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.mayocp.2011.11.007_bib17","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1023\/A:1008394827806","article-title":"Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients","volume":"11","author":"Haioun","year":"2000","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2011.11.007_bib18","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/annonc\/mdl434","article-title":"The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma","volume":"18","author":"Arkenau","year":"2007","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2011.11.007_bib19","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/annonc\/mdl327","article-title":"Incidence and risk factors of central nervous system recurrence in aggressive lymphoma\u2014a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)","volume":"18","author":"Boehme","year":"2007","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2011.11.007_bib20","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1200\/JCO.2008.16.8021","article-title":"Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516\u2014the Southwest Oncology Group","volume":"27","author":"Bernstein","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2011.11.007_bib21","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/annonc\/mdp432","article-title":"Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy","volume":"21","author":"Villa","year":"2010","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2011.11.007_bib22","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.hoc.2005.05.003","article-title":"Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma","volume":"19","author":"Bierman","year":"2005","journal-title":"Hematol Oncol Clin North Am"},{"issue":"7","key":"10.1016\/j.mayocp.2011.11.007_bib23","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1200\/JCO.1990.8.7.1163","article-title":"Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow","volume":"8","author":"Conlan","year":"1990","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.mayocp.2011.11.007_bib24","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1200\/JCO.2010.33.3419","article-title":"Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP","volume":"29","author":"Sehn","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2011.11.007_bib25","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2004-05-1982","article-title":"High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology","volume":"105","author":"Hegde","year":"2005","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mayocp.2011.11.007_bib26","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1200\/JCO.2008.17.7089","article-title":"Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry","volume":"27","author":"Quijano","year":"2009","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.mayocp.2011.11.007_bib27","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1200\/JCO.2009.27.3441","article-title":"Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy","volume":"28","author":"Phan","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2011.11.007_bib28","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"issue":"suppl 4","key":"10.1016\/j.mayocp.2011.11.007_bib29","article-title":"6-Year follow-up of the MINT study suggests a role for radiotherapy to bulky disease","volume":"22","author":"Pfreundschuh","year":"2011","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2011.11.007_bib30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/annonc\/mdq389","article-title":"The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67 scans","volume":"22","author":"Dorth","year":"2011","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.mayocp.2011.11.007_bib31","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.3324\/haematol.13440","article-title":"R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome","volume":"93","author":"Martin","year":"2008","journal-title":"Haematologica"},{"issue":"suppl 4","key":"10.1016\/j.mayocp.2011.11.007_bib32","article-title":"Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP and who respond to salvage chemotherapy","volume":"22","author":"Moore","year":"2011","journal-title":"Ann Oncol"},{"issue":"31","key":"10.1016\/j.mayocp.2011.11.007_bib33","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2011.35.4423","article-title":"The germinal center\/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed\/refractory diffuse large B-cell lymphoma: a Bio-CORAL study","volume":"29","author":"Thieblemont","year":"2011","journal-title":"J Clin Oncol"},{"issue":"15S","key":"10.1016\/j.mayocp.2011.11.007_bib34","first-page":"504s","volume":"29","author":"Stiff","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2011.11.007_bib35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bbmt.2009.08.011","article-title":"A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR","volume":"16","author":"Lazarus","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.mayocp.2011.11.007_bib36","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","article-title":"Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry","volume":"29","author":"van Kampen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2011.11.007_bib37","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbmt.2009.09.002","article-title":"Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Soci\u00e9t\u00e9 Fran\u00f2aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire","volume":"16","author":"Sirvent","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.mayocp.2011.11.007_bib38","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3816\/CLML.2010.n.056","article-title":"Surveillance computed tomography scans for patients with lymphoma: is the risk worth the benefits?","volume":"10","author":"Shenoy","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.mayocp.2011.11.007_bib39","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/cncr.22807","volume":"110","author":"Tsukamoto","year":"2007","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.mayocp.2011.11.007_bib40","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1182\/blood-2007-06-097238","article-title":"The role of FDG-PET scans in patients with lymphoma","volume":"110","author":"Seam","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mayocp.2011.11.007_bib41","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0002-9343(01)01117-2","article-title":"Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma","volume":"112","author":"Wirth","year":"2002","journal-title":"Am J Med"},{"issue":"10","key":"10.1016\/j.mayocp.2011.11.007_bib42","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/annonc\/mdn282","article-title":"Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma","volume":"19","author":"Elstrom","year":"2008","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2011.11.007_bib43","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.semradonc.2007.02.005","article-title":"2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas","volume":"17","author":"Specht","year":"2007","journal-title":"Semin Radiat Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2011.11.007_bib44","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/blood.V94.2.429","article-title":"Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging","volume":"94","author":"Jerusalem","year":"1999","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2011.11.007_bib45","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JCO.2001.19.2.414","article-title":"Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?","volume":"19","author":"Spaepen","year":"2001","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2011.11.007_bib46","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/11.suppl_1.S147","article-title":"18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas","volume":"11","author":"Mikhaeel","year":"2000","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2011.11.007_bib47","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2141.2001.03147.x","article-title":"Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma","volume":"115","author":"Naumann","year":"2001","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.mayocp.2011.11.007_bib48","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/annonc\/mdn671","article-title":"Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria","volume":"20","author":"Dupuis","year":"2009","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2011.11.007_bib49","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.mayocp.2011.11.007_bib50","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1002\/cncr.22276","article-title":"FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease","volume":"107","author":"Kostakoglu","year":"2006","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.mayocp.2011.11.007_bib51","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/annonc\/mdf256","article-title":"Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma","volume":"13","author":"Spaepen","year":"2002","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.mayocp.2011.11.007_bib52","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1182\/blood-2011-02-336990","article-title":"Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma","volume":"118","author":"Micallef","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2011.11.007_bib53","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1200\/JCO.2009.26.5942","article-title":"Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-Cell lymphoma","volume":"28","author":"Moskowitz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.mayocp.2011.11.007_bib54","article-title":"Limited-stage DLBCL patients with a negative PET scan following three cycles of R-CHOP have an excellent outcome following abbreviated immuno-chemotherapy alone","volume":"19","author":"Sehn","year":"2008","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2011.11.007_bib55","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2141.2011.08786.x","article-title":"Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy","volume":"154","author":"Corazzelli","year":"2011","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.mayocp.2011.11.007_bib56","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/annonc\/mdq671","article-title":"Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas","volume":"22","author":"Weidmann","year":"2011","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.mayocp.2011.11.007_bib57","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood.V114.22.408.408","article-title":"R-CHOP with etoposide substituted for doxorubicin (R-CEOP): excellent outcome in diffuse large B cell lymphoma for patients with a contraindication to anthracyclines","volume":"114","author":"Moccia","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2011.11.007_bib58","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2008"},{"key":"10.1016\/j.mayocp.2011.11.007_bib59","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"256","article-title":"Plasmablastic lymphoma","author":"Stein","year":"2008"},{"issue":"2","key":"10.1016\/j.mayocp.2011.11.007_bib60","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.clml.2011.03.008","article-title":"HIV-negative plasmablastic lymphoma: not in the mouth","volume":"11","author":"Castillo","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.mayocp.2011.11.007_bib61","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"247","article-title":"Lymphomatoid granulomatosis","author":"Pittaluga","year":"2008"},{"issue":"11","key":"10.1016\/j.mayocp.2011.11.007_bib62","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1182\/blood.V87.11.4531.bloodjournal87114531","article-title":"Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b","volume":"87","author":"Wilson","year":"1996","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2011.11.007_bib63","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1182\/blood-2011-03-321349","article-title":"How I treat primary CNS lymphoma","volume":"118","author":"Ferreri","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mayocp.2011.11.007_bib64","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdq548","article-title":"Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy","volume":"22","author":"Khimani","year":"2011","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1016\/j.mayocp.2011.11.007_bib65","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO.2010.31.4187","article-title":"First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial","volume":"29","author":"Vitolo","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2011.11.007_bib66","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2003.11.141","article-title":"Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group","volume":"21","author":"Zucca","year":"2003","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.mayocp.2011.11.007_bib67","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1200\/JCO.1995.13.6.1361","article-title":"Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy","volume":"13","author":"Touroutoglou","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.mayocp.2011.11.007_bib68","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"242","article-title":"Primary cutaneous DLBCL, leg type","author":"Meijer","year":"2008"},{"key":"10.1016\/j.mayocp.2011.11.007_bib69","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"227","article-title":"Primary cutaneous follicle centre lymphoma","author":"Willemze","year":"2008"},{"key":"10.1016\/j.mayocp.2011.11.007_bib70","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"252","article-title":"Intravascular large B-cell lymphoma","author":"Nakamura","year":"2008"},{"issue":"2","key":"10.1016\/j.mayocp.2011.11.007_bib71","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2141.2008.07338.x","article-title":"The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma","volume":"143","author":"Ferreri","year":"2008","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.mayocp.2011.11.007_bib72","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(09)70140-8","article-title":"Presentation and management of intravascular large B-cell lymphoma","volume":"10","author":"Shimada","year":"2009","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.mayocp.2011.11.007_bib73","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1182\/blood.V114.22.2947.2947","article-title":"Prognostic significance of circulating lymphoma cells in newly diagnosed diffuse large B-cell lymphoma (DLBCL)","volume":"114","author":"Muringampurath-John","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2011.11.007_bib74","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"267","article-title":"B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma","author":"Jaffe","year":"2008"},{"issue":"1","key":"10.1016\/j.mayocp.2011.11.007_bib75","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3960\/jslrt.51.7","article-title":"BCL2 and MYC dual-hit lymphoma\/leukemia","volume":"51","author":"Tomita","year":"2011","journal-title":"J Clin Exp Hematop"},{"issue":"8","key":"10.1016\/j.mayocp.2011.11.007_bib76","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","article-title":"Double-hit B-cell lymphomas","volume":"117","author":"Aukema","year":"2011","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.mayocp.2011.11.007_bib77","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.mayocp.2011.11.007_bib78","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Savage","year":"2009","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.mayocp.2011.11.007_bib79","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1200\/JCO.2010.32.8385","article-title":"The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective","volume":"29","author":"Salaverria","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2011.11.007_bib80","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s12185-010-0728-0","volume":"92","author":"Maruyama","year":"2010","journal-title":"Int J Hematol"},{"issue":"suppl 4","key":"10.1016\/j.mayocp.2011.11.007_bib81","article-title":"MYC + aggressive-B-cell lymphomas: novel therapy of untreated Burkitt lymhoma (BL) and MYC + diffuse large B-cell lymphoma (DLBCL) with DA-EPOCH-R","volume":"22","author":"Dunleavy","year":"2011","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2011.11.007_bib82","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3324\/haematol.2010.033167","article-title":"Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma","volume":"96","author":"Eberle","year":"2011","journal-title":"Haematologica"},{"issue":"suppl 4","key":"10.1016\/j.mayocp.2011.11.007_bib83","article-title":"Untreated primary mediastinal B-cell (PMBL) and mediastinal Grey Zone (MGZL) lymphomas: comparison of biological features and clinical outcome following DA-EPOCH-R without radiation","volume":"22","author":"Dunleavy","year":"2011","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2011.11.007_bib84","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3960\/jslrt.50.143","article-title":"Two cases of mediastinal gray zone lymphoma","volume":"50","author":"Minami","year":"2010","journal-title":"J Clin Exp Hematop"},{"issue":"6769","key":"10.1016\/j.mayocp.2011.11.007_bib85","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.mayocp.2011.11.007_bib86","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.mayocp.2011.11.007_bib87","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2011.11.007_bib88","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan","year":"2010","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.mayocp.2011.11.007_bib89","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1200\/JCO.2008.21.5020","article-title":"Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis","volume":"27","author":"Laurent","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.mayocp.2011.11.007_bib90","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"254","article-title":"ALK-positive large B-cell lymphoma","author":"Delsol","year":"2008"},{"issue":"18","key":"10.1016\/j.mayocp.2011.11.007_bib91","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"issue":"15S","key":"10.1016\/j.mayocp.2011.11.007_bib92","first-page":"512s","article-title":"Durable remissions with brentuximab vedotin (SGN-35): updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) [abstract 8032]","volume":"29","author":"Pro","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611000231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611000231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:27:00Z","timestamp":1758418020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611000231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0025619611000231"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2011.11.007","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"My Treatment Approach to Patients With Diffuse Large B-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2011.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}